Forte Biosciences

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Evercore ISI Annual HealthCONx Conference on December 3, 2020. Webcast Information Forte management will host a webcast on Thursday December 3rd, 2020 at 11:20 AM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Stifel 2020 Virtual Healthcare Conference. Webcast Information Forte management will host a webcast on Wednesday November 18th, 2020 at 2:40 to 3:10 PM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/webcast/sti

Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update. “This was an eventful quarter for Forte with significant progress in advancing FB-401 for the treatment of atopic dermatitis.” said Paul Wagner, Ph.D., CEO of Forte Biosciences “The initiation of our randomized trial in atopic dermatitis patients, including adults a

Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET to discuss third quarter 2020 results and to provide a general business update. Conference Call and Webcast Information Forte management will host a conference call and webcast on November 9, 2020 at 4:30 P

Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035 shares of its common stock, which includes 210,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares at a public offering price of $28.50 per share, less the underwriting discounts and commissions. All of the shares were of

Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Forte intends to use the net proceeds of the offering for working capital and general corporate purposes, wh

Forte Biosciences Announces Proposed Public Offering of Common Stock

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic de

  Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the clinical trial of FB-401 for the treatment of atopic dermatitis. The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis (AD). The primary endpoint of the tri

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc.

Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine

Forte Biosciences (NASDAQ: FBRX) shares are trading higher on Friday after getting two upgrades.

Why Forte Biosciences's Stock Is Trading Higher Today

News for Forte Biosciences Stock (FBRX)